Telomir director exchanges 25K stock options

Telomir Pharmaceuticals, Inc. director Matthew Paul Del Giudice reported a restructuring of his stock options with no net change in option count.

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. director Matthew Paul Del Giudice reported a restructuring of his stock options with no net change in option count. He agreed to cancel 25,000 fully exercisable incentive stock options for common stock with a $5.02 exercise price and a August 27, 2034 expiration, as a disposition back to the issuer.

In exchange, he received a new grant of 25,000 incentive stock options for common stock with a lower exercise price of $1.30 per share and a May 21, 2036 expiration. Following these transactions, he holds 25,000 stock options directly, and no common shares were bought or sold in the market.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Del Giudice Matthew Paul

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Incentive Stock Options (right to buy)	25,000	$0.00	$0.00
Disposition	Incentive Stock Options (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Incentive Stock Options (right to buy) — 25,000 contracts (Direct)

Footnotes (2)

1. F1. The options are fully exercisable.
2. F2. The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price.

Key Figures

Options cancelled: 25,000 options Cancelled option exercise price: $5.02/share Cancelled option expiration: August 27, 2034 +4 more

7 metrics

Options cancelled 25,000 options Incentive stock options disposed to issuer on May 21, 2026

Cancelled option exercise price $5.02/share Exercise price of option grant dated August 27, 2024

Cancelled option expiration August 27, 2034 Original expiration of disposed incentive stock options

New options granted 25,000 options Incentive stock options granted on May 21, 2026

New option exercise price $1.30/share Exercise price of newly granted incentive stock options

New option expiration May 21, 2036 Expiration date of newly granted incentive stock options

Options held after transactions 25,000 options Total derivative holdings following reported Form 4 transactions

Key Terms

Incentive Stock Options, Disposition to issuer, Grant, award, or other acquisition, exercise price, +1 more

5 terms

Incentive Stock Options financial

"Incentive Stock Options (right to buy)"

Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.

Disposition to issuer financial

"transaction_code_description: Disposition to issuer"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 5.0200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-21T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Telomir Pharmaceuticals (TELO) director report in this Form 4?

The director reported canceling 25,000 incentive stock options and receiving a new grant of 25,000 options. The change updates exercise price and expiration but leaves his total option count unchanged at 25,000, with no open-market share purchases or sales.

How many Telomir (TELO) stock options were cancelled and re-granted?

He cancelled 25,000 incentive stock options and received a new grant of 25,000 options. The one-for-one exchange keeps his derivative holdings at 25,000 options, changing only the terms, not the number of options or common shares outstanding.

What are the exercise prices of the Telomir (TELO) options in this Form 4?

The cancelled incentive stock options had a conversion or exercise price of $5.02 per share. The new incentive stock options were granted with a lower exercise price of $1.30 per share, improving the economic terms of his compensation-linked option position.

What are the expiration dates of the Telomir (TELO) stock options mentioned?

The cancelled option grant was scheduled to expire on August 27, 2034. The newly granted 25,000 incentive stock options expire later, on May 21, 2036, extending the director’s time window to exercise these compensation-related options for common stock.

Did the Telomir (TELO) director buy or sell any common shares in this filing?

No common shares were bought or sold. The filing reports only derivative transactions involving incentive stock options: a disposition of 25,000 options back to the issuer and a new grant of 25,000 options, leaving his direct common share position unchanged.

How did this Telomir (TELO) Form 4 affect the director’s total option holdings?

After cancelling and re-granting 25,000 incentive stock options, the director’s total reported option holdings stand at 25,000. The transactions adjust exercise price and expiration date but do not increase or decrease the aggregate number of options he holds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/22/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Del Giudice Matthew Paul

(Last) (First) (Middle)

C/O TELOMIR PHARMACEUTICALS, INC.

900 WEST PLATT STREET, SUITE 200

(Street)

MIAMI FLORIDA 33606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Telomir Pharmaceuticals, Inc. [ TELO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Options (right to buy)	$1.3	05/21/2026		A		25,000		(1)	05/21/2036	Common Stock	25,000	(2)	25,000(2)	D
Incentive Stock Options (right to buy)	$5.02	05/21/2026		D			25,000	08/27/2024	08/27/2034	Common Stock	25,000	(2)	0	D

Explanation of Responses:

1. The options are fully exercisable.

2. The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price.

	/s/ Matthew Del Giudice	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)